Skip to main content
. 2015 Dec 29;5(2):265–274. doi: 10.1002/cam4.593

Figure 1.

Figure 1

(A) Relapse‐free survival (RFS) of the patients according to BM‐WT1 after 1st consolidation. At the median follow up (12.5 months): RFS 82% (95% CI 72–92) for BM‐WT1 < 121/104 ABL copies versus 51% (95% CI 30–72) for BM‐WT1 ≥ 121/104 ABL copies (assessment after 1st consolidation). (B) RFS of the patients according to Leukemia Associated Immunophenotype (LAIP) after 1st consolidation. At the median follow up (12.5 months): RFS 81% (95% CI 70–92) for LAIP ≥ 0.2% versus 57% (95% CI 37–77) for LAIP decrease <0.2% (assessment after 1st consolidation). (C) RFS of the patients according to PB‐WT1 after intensification (1st cycle). At the median follow up (12.5 months): RFS 95% (95% CI 88–100) for PB‐WT1 < 16/104 ABL copies versus 43% (95% CI 22–64) for PB‐WT1 ≥ 16/104 ABL copies (assessment after postintensification – 1st cycle).